Focus topics


mRNA vaccine passes phase 1 clinical trials

One of China’s mRNA vaccines against Covid is expected to achieve 95 percent efficacy in tests. This was shown by data from the first phase of clinical trials, reports business portal Caixin. The vaccine was jointly developed by Walvax Biotechnology and Suzhou Abogen Biosciences, as well as the Academy of Military Sciences of the Chinese People’s Liberation Army, according to Caixin. It bears the designation Arcov.

Continue reading now

Get 30 days of free access to the Professional Briefing to read these and more quality news every day.

Are you already a guest at the China.Table? Log in now